ANKRD30A
- Known as:
- ANKRD30A
- Catalog number:
- 001628A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- ANKRD30A
Related genes to: ANKRD30A
- Gene:
- ANKRD30A NIH gene
- Name:
- ankyrin repeat domain 30A
- Previous symbol:
- -
- Synonyms:
- NY-BR-1
- Chromosome:
- 10p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-12
- Date modifiied:
- 2014-11-19
Related products to: ANKRD30A
Related articles to: ANKRD30A
- Cancer therapeutics frequently fail in clinical trials because of poor therapeutic index (efficacy-to-toxicity ratio). We systematically identified targets likely to have a good therapeutic index, revealing insulin receptor substrate 4 (IRS4) as a dependency in -expressing cancers. Pan-cancer analysis of pediatric-enriched cancers revealed expression consistent with dependency in 68% of choroid plexus, 37% of malignant rhabdoid, 31% of NUT midline, and 5% of osteosarcomas, while in adult cancers, it was expressed in 8% of uterine leiomyosarcomas and 1 to 2% of lung squamous, stomach, and breast carcinomas. expression in adult tumors was associated with enhancer hijacking rearrangements, including recurrent and in breast cancer, while rhabdoid and NUT midline cancers expressed epigenetically. IRS4 fueled cancer dependency through PI3K-Akt activation, and domain analysis revealed the PH and PTB domains, which have a predicted drug pocket, to be dispensable, suggesting degradation-based modalities. These data reveal IRS4 as a target in IRS4-expressing cancers and suggest inhibitory approaches. - Source: PubMed
Publication date: 2026/04/29
Banu KhadijaKhan Mohammad AslamLi SihanReynolds-Gagliano MorganWang XiaofeiMobley Robert JBarnett Kelly RWielgosz Matthew MBauler MatthewWincek ChristopherKodali KiranWang WeiPagala VishwajeethHigh Anthony APutnam DanielKotecha Rishi SCheung Laurence CMa XiaotuThrom Robert EPruett-Miller Shondra MSavic DanielBrady Samuel W - Extramammary Paget's disease (EMPD) is a frequently recurring malignant neoplasm with metastatic potential. The exact origin of the tumor is still undefined. To explore potential cellular origin-related signals and depict a relatively comprehensive cellular landscape of EMPD, we collected 50,180 cells from patients with EMPD. We detected a distinct basal keratinocyte cell population characterized by New York Breast-1 (NY-BR-1) expression, which exhibited a transcriptional trajectory toward Paget-like phenotype. We also presented a comprehensive single-cell profile of immune cells and fibroblasts in EMPD. The fibroblasts exhibited a markedly central position in outgoing and incoming signaling interactions. The upregulation of the MK pathway and the downregulation of the MIF pathway in EMPD may promote fibroblast-immune crosstalk and tumor progression. This study provided a novel perspective on potential origin-related transcriptional programs in EMPD and highlighted a global reprogramming of cell-cell communication in EMPD, driven predominantly by fibroblast-derived interactions. - Source: PubMed
Publication date: 2026/03/12
Li RuiRen FeifeiLi HongyangSun QiDing MeilinLi DongqingCheng WeiChen HaoSun JianfangJiang MingjunWu XinfengHuang LimingZhao LiangYang YongZheng MeilingZhang Wei - Urothelial cancer, the most frequently diagnosed cancer of the urinary tract, is the tenth most common cancer globally. DNA primase subunit 1 (PRIM1) is necessary for cancer onset and progression. PRIM1 also serves as a prognostic indicator in invasive breast carcinoma, gastric cell carcinoma, and liver hepatocellular carcinoma. Despite its importance, little is currently known regarding PRIM1's clinical function in urothelial cancer. - Source: PubMed
Publication date: 2026/01/07
Al-Hassany Ban AAl-Sudani Israa M - NCI-MATCH (EAY131) is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatments. Arm Y evaluated capivasertib, a pan AKT inhibitor, in patients with an -mutated tumor. Here, we report on the translational objectives of the study, a molecular and genomic analysis of specimens to identify potential biomarkers of response or resistance to capivasertib. - Source: PubMed
Publication date: 2025/03/28
McCourt Carolyn KGross JacobKalinsky KevinGuan PingMcShane Lisa MWang VictoriaO'Dwyer Peter JLahey Matthew TMaican CaydenBu XiangningPatton DavidHarris Lyndsay N - Immunotherapy has opened up a new era of individualized treatment for non-small cell lung cancer (NSCLC) with negative driver gene mutations. Anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies have been the main options for immunotherapy over the past decade. Screening for predictive markers of anti-PD-1/PD-L1-responsive patients remains a focus in the field of immunotherapy, especially on the protein level in which relevant proteomic biomarkers are still lacking. - Source: PubMed
Publication date: 2024/01/29
Zhang XiaoshenGao GuanghuiZhang QianZhao SongchenLi XuefeiCao WeiLuo HengZhou Caicun